FDA approves pritelivir to treat mucocutaneous lesions caused by HSV infection
The Food and Drug Administration (FDA) has approved the antiviral drug pritelivir for immunocompromised adults who have mucocutaneous lesions caused by herpes simplex virus (HSV) infection and who have not responded to other therapies (acyclovir, valacyclovir, or famciclovir). Pritelivir is a first-in-class, oral HSV helicase-primase inhibitor that is active against both HSV-1 and HSV-2.
The approval follows the completion of a phase 3 randomized controlled trial which evaluated the efficacy of pritelivir in immunocompromised participants with mucocutaneous HSV infection who did not respond to other antivirals.[66] While results of the study are yet to be published, according to the FDA, 63% of patients receiving pritelivir had all lesions completely healed by 28 days compared with 34% of patients receiving either acyclovir, valacyiclovir, or famciclovir. The most common adverse effect was headache.
Pritelivir is expected to be available in the US by the end of 2026. It has not been approved in other countries as yet and is not recommended by any current major guidelines.
Resumo
Definição
History and exam
Key diagnostic factors
- dysuria (in women)
- lymphadenopathy
- genital ulcer
- oral ulcer
- fever
Other diagnostic factors
- tingling sensation
- headache/aseptic meningitis
Risk factors
- HIV infection (risk factor for clinical disease)
- use of immunosuppressive drugs (risk factor for clinical disease)
- female sex (risk factor for seropositivity)
- black race (risk factor for seropositivity)
- increasing age (risk factor for seropositivity)
- high-risk sexual behavior (risk factor for seropositivity)
- lack of condom use (risk factor for seropositivity)
Diagnostic tests
1st tests to order
- HSV polymerase chain reaction (PCR)
- viral culture
Tests to consider
- Glycoprotein G-based type-specific serology (gG1 and gG2)
Treatment algorithm
CNS involvement: encephalitis or meningitis
disseminated visceral involvement: esophagitis, pneumonitis, or hepatitis
genital disease: first episode, immunocompetent, nonpregnant
genital disease: first episode, immunocompromised, nonpregnant
genital disease: recurrent episode, immunocompetent, nonpregnant
genital disease: recurrent episode, immunocompromised, nonpregnant
genital disease: primary or first-episode, pregnant
genital disease: recurrent episode, pregnant
oral disease: first episode, immunocompetent
oral disease: first episode, immunocompromised
oral disease: recurrent episode, immunocompetent
oral disease: recurrent episode, immunocompromised
genital disease: sexually active or frequent severe recurrences, immunocompetent, nonpregnant
genital disease: sexually active or frequent severe recurrences, immunocompromised, nonpregnant
genital disease: pregnant
oral disease: frequent severe recurrences, immunocompetent
oral disease: frequent severe recurrences, immunocompromised
Contributors
Authors
Benjamin D. Lorenz, MD
Assistant Professor
Division of Hospital Medicine
MedStar Georgetown University Hospital
Washington, DC
利益声明
BDL declares that he has no competing interests. Since completing the 2024 review, BDL has become an employee of Moderna and has resigned as a contributor.
鸣谢
Dr Benjamin D. Lorenz would like to gratefully acknowledge Dr Christine Johnson and Dr Anna Wald, previous contributors to this topic.
利益声明
CJ reports funding from AiCuris; grants from Agenus, Gilead, Genocea, Sanofi, and Vical to conduct clinical research studies; and royalties from Up To Date. AW reports grants from Agenus, Gilead, Genocea, Sanofi, and Vical to conduct clinical research studies. AW receives royalties from Up To Date. AW is an NIH grant recipient (NIH AI30731 and AI071113) and a consultant for Aicuris, Eisai, and Amgen.
同行评议者
Giuseppe Pizzo, DDS
Associate Professor
Department of Surgical, Oncological and Oral Sciences
School of Dentistry
University of Palermo
Palermo
Italy
利益声明
GP declares that he has no competing interests.
Paul Adamson, MD, MPH
Assistant Clinical Professor of Medicine
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
利益声明
PA declares that he has no competing interests.
Nicholas Van Wagoner, MD, PhD
Associate Professor of Medicine
University of Alabama
Birmingham, AL
利益声明
NVW declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
参考文献
关键文献
Centers for Disease Control and Prevention. Morbidity and mortality weekly report: sexually transmitted infections treatment guidelines, 2021. Jul 2021 [internet publication].全文
Patel R, Kennedy OJ, Clarke E, et al. 2017 European guidelines for the management of genital herpes. Int J STD AIDS. 2017 Dec;28(14):1366-79.全文 摘要
American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 220: management of genital herpes in pregnancy. May 2020 [internet publication].全文
British Association for Sexual Health & HIV; Royal College of Obstetricians and Gynaecologists. Management of genital herpes in pregnancy. Oct 2014 [internet publication].全文
参考文献
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

鉴别诊断
- Syphilis
- Chancroid
- Lymphogranuloma venereum
更多 鉴别诊断指南
- Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV
- Sexually transmitted infections treatment guidelines, 2021
更多 指南患者教育信息
Cold sores
Genital herpes
更多 患者教育信息登录或订阅即可浏览 BMJ Best Practice 临床实践完整内容
内容使用需遵循免责声明